Cerevel Therapeutics

Also Clin3 late Parkinson's; Emraclidine Clin2 schizophrenia/psychosis; Darigabat Clin2 epilepsy, Clin1 panic disorder; CVL-871 Clin2 dementia-related apathy; CVL-354 Clin1 depression, substance use disorder; CVL-047 Clin0 depression, schizophrenia; 2 undisclosed programs RD schizophrenia/psychosis, Parkinson's

Cerevel Therapeutics is understanding the brain to treat neuroscience diseases. Many diseases are caused by malfunctions of neurocircuitry affecting millions of people worldwide. Cerevel is striving to understand why these deficits in neurocircuitry occur and how they can be treated. Using advancements in chemistry, genomics and proteomics, Cerevel is identifying small molecules that target neuronal receptors to normalize neural network function. Cerevel currently has a diverse pipeline with therapies addressing various neurological disorders including Parkinson’s, Epilepsy and Anxiety in pre-clinical and clinical stages.

Jobs: